Fig. 1 · Structure

Documents & Downloads

Reboxetine mesylate

Cat. No. A11919 CAS 98769-84-7
Reboxetine is an antidepressant compound that selectively inhibits norepinephrine uptake (IC50s = 8.2 and 1,070 nM for norepinephrine and serotonin transporters, respectively). It displays greater than 1,000-fold affinity for binding rat norepinephrine receptors compared to serotonin, histamine, acetylcholine, or dopamine receptors (Kis = 1.1, 129, 1,400, 3,900, and >10,000 nM, respectively).

In Stock

Publications for Reboxetine mesylate

1 publication citing this product

  1. Antonia Donat, .et al. , iScience, 2023, Aug 29;26(10):107761 PMID: 37720081

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
norepinephrine reuptake Ki 8.2 nM

In Vivo Studies

In female C57BL/6J mice with a stabilized femoral osteotomy, reboxetine mesylate (15 mg/kg intraperitoneally once daily from surgery) improved day-28 callus bridging and mechanical resistance versus saline. Early and intermediate callus measurements showed no significant changes. Effects elsewhere in the skeleton differed by site: spinal trabecular bone volume decreased, whereas contralateral femoral cortical thickness increased. These findings are specific to this mouse model and do not establish improved fracture healing in humans. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Site-dependent skeletal effects and fracture healing in female mice

Animal study · Female C57BL/6J wild-type mice, 12–14 weeks old at surgery, body weight >20 g; femoral osteotomy stabilized by external fixation. [1]

A single systemic treatment design examined fracture healing and the intact skeleton at multiple sacrifice times. Favorable day-28 repair outcomes coexisted with spinal trabecular bone loss. No human inference or quantified NET inhibition is established.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Callus structure and cartilage/mineralized area at days 7, 14 and 21reported direction No significant differences reported versus vehicle.[1]
Day-28 callus bridging, maximum force and work to structural failurereported direction Improved callus bridging and increased mechanical resistance; callus bone volume and tissue volume not significantly altered.[1]
Day-21 spinal trabecular bone and contralateral femoral cortexreported direction Spinal BV/TV decreased with increased osteoclast indices; femoral cortical thickness and endocortical osteoblast number increased. Distal femoral trabecular measures, cortical porosity and cortical osteoclast numbers were not significantly altered.[1]
Day-21 callus osteoblast and osteoclast parametersreported direction Osteoblast number and surface increased; osteoclast parameters not significantly altered.[1]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
Once daily
Treatment course
Started at surgery; continued to designated sacrifice time points. Adopted outcome measurements: days 7, 14, 21 and 28.
Vehicle
0.9% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Reboxetine mesylate versus saline
15 mg/kg (as reported; no salt-to-base conversion)
Vehicle injections (0.9% saline) under the same fracture model and perioperative treatment.Improved late callus bridging/mechanics with unchanged early structural endpoints and adverse spinal trabecular effects; see measurements.[1]
Reboxetine mesylate versus saline
Model: Female C57BL/6J wild-type mice, 12–14 weeks old at surgery, body weight >20 g; femoral osteotomy stabilized by external fixation.
Reported limits: No lot-specific composition or enantiomeric assay. Exact mechanical effect sizes not extracted from graphs.
Methods and source locations

Compound reported in the paper: Reboxetine mesylate; Compound label in the paper: AdooQ BioScience A11919; CAS 98769-84-7

Reported use of catalog A11919 in a female-mouse bone-repair model; no validation of current AdooQ lots, human healing, or isolated enantiomer potency.

Figures 2–5, associated Results and captions; key resources table; STAR Methods: Animal experiments, Materials, Surgery and treatment, Micro-computed tomography, Histomorphometry, Biomechanics, Quantification and statistical analysis; Limitations of the study

Callus structure and cartilage/mineralized area at days 7, 14 and 21: Micro-CT and Movat pentachrome histomorphometry; n = 6 mice per group and time point; unpaired two-tailed Student’s t tests. — Figures 3B and 4B, captions; corresponding Results; STAR Methods: Quantification and statistical analysis

Day-28 callus bridging, maximum force and work to structural failure: Blinded semiquantitative micro-CT bridging assessment; three-point bending; n = 6 mice per group. Figure 5D labels p = 0.002 for maximum force and p = 0.04 for work; no graph-derived effect sizes extracted. — Figure 5A–D and caption; Results: Reboxetine improves late-stage fracture healing; STAR Methods: Micro-computed tomography, Biomechanics

Day-21 spinal trabecular bone and contralateral femoral cortex: Histomorphometry and micro-CT; n = 6 mice per group. Boxplots: median, 25th/75th quantiles, minimum/maximum whiskers. — Figure 2A–F and caption; Results: Systemic reboxetine treatment exerts distinct effects in the non-fractured skeleton

Day-21 callus osteoblast and osteoclast parameters: Histomorphometry; n = 6 mice per group; unpaired two-tailed Student’s t tests. — Figure 4C–D and caption; corresponding Results

Reboxetine mesylate versus saline · STAR Methods: Animal experiments, Materials, Surgery and treatment; Figures 2–5 and captions

Specifications

Manufacturer Adooq Bioscience
CAS Number 98769-84-7
Formula C19H23NO3.CH4SO3
Molecular Weight 409.5
SMILES
CCOC1=CC=CC=C1O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3.CS(=O)(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 81 mg/mL (197.8 mM)
Water 81 mg/mL (197.8 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Antonia Donat, Shan Jiang, Weixin Xie, et al. The selective norepinephrine reuptake inhibitor reboxetine promotes late-stage fracture healing in mice iScience (2023). PMID: 37720081 DOI: 10.1016/j.isci.2023.107761 Source material

Publications

1 publication citing this product

  1. Antonia Donat, .et al. , iScience, 2023, Aug 29;26(10):107761 PMID: 37720081

Added to your cart

View Cart Checkout
Loading...